在接种 BNT162b2、ChAdOx1 或 CoronaVac 并进行异源加强针后，成年人感染和完全接种疫苗后中和奥密克戎变异株的能力降低。

Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Avenida Brasil 4365, Rio de Janeiro, RJ, 21040-900, Brazil.

Institute of the Environment and Sustainability, University of California Los Angeles, Los Angeles, 90095, USA.

Sci Rep. 2023 May 8;13(1):7437. doi: 10.1038/s41598-023-34035-9.

COVID-19 vaccines have dramatically reduced rates of severe infection requiring hospitalization. However, SARS-CoV-2 variants have reduced vaccine effectiveness at preventing any symptomatic infection. This real-world study analyzed binding and neutralizing antibodies generated after complete vaccination and boosting across three vaccine platforms. Binding antibodies decayed most slowly in people under 60 with hybrid immunity. Neutralizing antibodies against Omicron BA.1 were reduced compared to other variants. The anamnestic anti-spike IgG response to the first boost was more pronounced than after the second boost. Monitoring of the effects of SARS-CoV-2 mutations on disease severity and the effectiveness of therapeutics is warranted.

COVID-19 疫苗显著降低了严重感染需要住院治疗的发生率。然而，SARS-CoV-2 变体降低了疫苗预防任何有症状感染的效力。这项真实世界的研究分析了在三种疫苗平台上完全接种和加强接种后产生的结合抗体和中和抗体。在有混合免疫力的 60 岁以下人群中，结合抗体的衰减速度最慢。与其他变体相比，对奥密克戎 BA.1 的中和抗体减少。与第二次加强针相比，第一次加强针后针对刺突蛋白的记忆性 IgG 反应更为明显。有必要监测 SARS-CoV-2 突变对疾病严重程度和治疗效果的影响。